Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — MRI Interventions — Investor Presentation (November 2015)
30 slides from Clearpoint Neuro's investor presentation, Nov 3, 2015
Slide 1: Investor Presentation November 3, 2015
Exhibit 99.2 Ticker: MRIC Investor Presentation November 3, 2015 Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2015 MRI INTERVENTIONS, INC. | 1
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as "an
Slide 3: MRI Interventions Opportunity
MRI Interventions Opportunity Market Market is large and growing 55,000 potential ClearPoint procedures across multiple therapies Navigation System for Multiple Therapies Electrode placement for Deep Brain Stimulation Laser Ablation for ablation of epileptic foci or Brain Tumors Brain Tumor Biopsy f
Slide 4: MRI Interventions: Real Time MRI Guided Surgery
MRI Interventions: Real Time MRI Guided Surgery First-to-market technology platform enabling real-time MRI guided surgery; FDA-cleared, CE-marked and 40+ ClearPoint sites Focused commercialization of neuro platform underway, gaining traction; recent restructuring complete Attractive razor/razorblade
Slide 5: Leadership – Significant Med Device Experience
Leadership –Significant Med Device Experience Key Management Executive Title Prior Experience Frank Grillo President, CEO Peter Piferi COO Wendelin Maners VP Marketing Robert Korn VP Sales Hal Hurwitz CFO Board of Directors Kimble Jenkins, Exec Chair Maria Sainz Dr. Phillip Pizzo Pascal Girin Timoth
Slide 6: Technology: ClearPoint Neuro Navigation System
Technology: ClearPoint® Neuro Navigation System Navigation System consisting of Integrated Devices and Software for Real-Time, MRI Guided, Minimally Invasive Neurosurgical Procedures Visualize •Identify target Verify •Observe progress to target Confirm •Confirm precise placement at target © 2015 MRI
Slide 7: Without ClearPoint, minimally invasive neuro procedures are performed blind
Without ClearPoint, minimally invasive neuro procedures are performed “blind” Conventional Stereotactic Procedure ClearPoint Neuro Procedure No real-time visualization Next generation platform enabling real time, MRI guided, minimally invasive brain surgery © 2015 MRI INTERVENTIONS, INC. | 7
Slide 8: ClearPoint Neuro Navigation System
ClearPoint® Neuro Navigation System 1.5T or 3T MR Scanners, also works in intraop MRI Suites MRI Safe Disposable Components: SmartGrid® and SmartFrame® – Integrated ClearPoint Targeting and Trajectory Precision ClearPoint® Drape provides sterile procedural field in any diagnostic or intraoperative M
Slide 9: ClearPoint Procedure Overview: Target Selection & Entry Planning
ClearPoint Procedure Overview Target Selection & Entry Planning © 2015 MRI INTERVENTIONS, INC. | 9
Slide 10: ClearPoint Procedure Overview: Trajectory Alignment & Device Insertion
ClearPoint Procedure Overview SmartFrame® Trajectory Guide SmartFrame® Hand Controller Trajectory Alignment & Device Insertion © 2015 MRI INTERVENTIONS, INC. | 10
Slide 11: ClearPoint Procedure Overview: Delivery of Neurological Therapy
ClearPoint Procedure Overview Delivery of Neurological Therapy Drug Delivery 1 Electrode Placement Laser Ablation 2 (1) Drug Delivery - The SmartFlow® cannula received 510(k) clearance for injection of cytarabine, a chemotherapy drug, to the ventricles or removal of CSF from the ventricles during in
Slide 12: ClearPoint Hospital Economics
ClearPoint Hospital Economics Increase Patients Better patient experience provides hospitals the opportunity to reach additional patient populations that may otherwise forego surgery 65% of eligible DBS patients refuse treatment, due to fear of surgery (1) Established, Attractive Reimbursement Move
Slide 13: Multi-Therapy MRI-Guided Navigational System
Multi-Therapy MRI-Guided Navigational System Leading Neurosurgeon Supporters Dr. Philip Starr ASSFN Past President Dr. Paul Larson UCSF & VA Dr. Robert Gross Emory University Dr. Robert Wharen, Jr. Mayo Clinic -Jacksonville Dr. Krys Bankiewicz Bankiewicz Lab, UCSF Dr. Russ Lonser OSU -NIH Strong Pee
Slide 14: Strong Intellectual Property
Strong Intellectual Property Close to 100 issued patents around the world 50+ U.S. Patents 45+ OUS Patents 40+ U.S. Patent Applications 50+ OUS Patent Applications Issued patents cover areas such as: MRI-guided surgical systems that include software and devices; the SmartFrame® trajectory guide; oth
Slide 15: Patient Impact: Martin's Story
Patient Impact Martin’s Story ClearPoint-Enabled Electrode Placement © 2015 MRI INTERVENTIONS, INC. | 15
Slide 16: Patient Benefit
Patient Benefit Minimally Invasive Procedure 7 days after ClearPoint procedure Arrow Indicates Surgery Site © 2015 MRI INTERVENTIONS, INC. | 16
Slide 17: ClearPoint Drug Delivery
ClearPoint Drug Delivery • MR visualization of neuro target • MR-guided placement of catheter • Therapeutic agent delivered under MR-guidance* Specialized drug delivery cannula’s catheters Drug infusion is visible real time under MRI Conclusion: The ClearPoint system allows Real-time Convection-enha
Slide 18: MRI's Unique Opportunity in Drug Delivery
MRI’S Unique Opportunity in Drug Delivery Provides MRIC with “biotech-like upside” without “all or nothing downside” Major Challenges in Delivering Drugs to the Brain - Blood brain barrier blocks systemic delivery of almost all drugs – 98% of small molecules - Direct injection without ClearPoint is
Slide 19: The ClearPoint Difference
The ClearPoint Difference Without ClearPoint (Stereotactic) No direct visualization; Performed in anoperating room Patient may be awake forown brain surgery(1) Long procedures – Can be up to 8 hours Accuracy to target based on prior images May require OR and MRI for same procedure (laser ablation) P
Slide 20: ClearPoint Revenue Model
ClearPoint Revenue Model BUSINESS MODEL – RAZOR / RAZORBLADE ClearPoint Hardware/Software: $100,000 - $150,000 ASP ClearPoint Disposables: $7,500 (average) ASP per procedure with strong margins Recurring revenue from the sale of disposables Procedures covered by existing inpatient DRG reimbursement
Slide 21: Growing the ClearPoint Footprint
Growing the ClearPoint Footprint Installed Base of 39 sites in the US © 2015 MRI INTERVENTIONS, INC. | 21
Slide 22: ClearPoint US Market Opportunity
ClearPoint US Market Opportunity Parkinson’s Epilepsy Brain Tumors Total Prevalence (US) 1,500,000 2,200,000 80,000(annual diagnosis) Prevalence – Drug Treatment Resistant (DTR) 125,000 264,000 Incidence – DTR 7,500 18,000 Resections: 80,000 Stereotactic Biopsy: 10,000 ClearPoint Enabled Therapy Ele
Slide 23: ClearPoint Future Opportunities
ClearPoint Future Opportunities Multiple Therapies for Future Growth Neuro Disorder Patient Population Treatment Resistant Patient Population ClearPoint Enabled Therapy Current Status Dystonia 250,000 25,000 DBS Active Use, HDE OCD 3,300,300 100,000 DBS Active Use, HDE Severe Depression 6,000,000 1,
Slide 24: ClearPoint Consumable Revenues
ClearPoint Consumable Revenues Consumable Revenue $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2013 2014 2015 © 2015 MRI INTERVENTIONS, INC. | 24
Slide 25: Total Revenue, 2013 - 2015
Total Revenue, 2013 - 2015 $1,400,000 Total Revenue $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2013 2014 2015 Consumables Capital / Service Other © 2015 MRI INTERVENTIONS, INC. | 25
Slide 26: Cash Flow From Operations
Cash Flow From Operations $0 -$500,000 -$1,000,000 -$1,500,000 -$2,000,000 -$2,500,000 -$3,000,000 Q1 Q2 Q3 Q4 Q1 Q2 2014 2015 © 2015 MRI INTERVENTIONS, INC. | 26
Slide 27: Commercial Priorities
Commercial Priorities Increase Utilization • Focus on adding surgeons at existing accounts • Target high volume sites, including epilepsy and tumor neurosurgeons within each account; gain greater share of their procedures • Add Clinical Specialists and sales reps to commercial team; compensate for u
Slide 28: R&D Priorities
R&D Priorities Software 2.0 • Significant upgrade to existing software; includes real time fusion, enhanced graphic and User Interface • Technology licenses near complete with three additional software companies for this effort OR SmartFrame • Through partnership(s), expand our products and brand in
Slide 29: At the Center of an Emerging Industry Trend
At the Center of an Emerging Industry Trend ClearPoint Electrode Placement ClearPoint Laser Catheter Placement ClearPoint Performed in MRI Scanners ClearTrace Ablation and Drug Delivery ClearPoint Direct Drug Delivery Real Time MRI-Guided Procedures MRIC is at the point of convergence in an industry
Slide 30: MRI Interventions, Inc. Contact
Ticker: MRIC MRI Interventions, Inc. Irvine, CA 949.900.6833 mriinterventions.com Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2015 MRI INTERVENTIONS, INC. | 30
MRI Interventions — Investor Presentation (November 2015) on 6ix